General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -0.09 | N/A | N/A | N/A |
2024-03-05 | 2023-12 | -0.08 | -0.12 | -0.04 | -50.00% |
2023-11-06 | 2023-09 | -0.11 | -0.03 | 0.08 | 72.73% |
2023-11-06 | 2023-09 | -0.11 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.11 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.11 | -0.1 | 0.01 | 9.09% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-09 | Wedbush | Upgrade | Outperform | Outperform |
2023-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-21 | Wedbush | Upgrade | Outperform | Outperform |
2023-09-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-20 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-07-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-06 | BARBER DANIEL | Chief Executive Officer | 883.30K | Stock Award(Grant) |
2024-03-06 | BOYD PETER E | Officer | 246.00K | Stock Award(Grant) |
2024-03-06 | BRAENDER LORI J | General Counsel | 323.76K | Stock Award(Grant) |
2024-03-06 | JUNG CASSIE | Officer | 249.23K | Stock Award(Grant) |
2021-08-25 | KENDALL KEITH J. | Chief Executive Officer | 637.15K | Stock Gift |
2024-03-06 | KRAUS CARL N | Officer | 262.50K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Bratton Capital Management, LP | 9.81M | 16.19M | 14.70% |
2023-06-29 | Vanguard Group Inc | 1.56M | 2.57M | 2.34% |
2023-06-29 | Renaissance Technologies, LLC | 1.23M | 2.03M | 1.84% |
2023-06-29 | Armistice Capital, LLC | 1.16M | 1.91M | 1.74% |
2023-09-29 | Vahanian & Associates Financial Planning Inc. | 722.11K | 1.10M | 1.08% |
2023-06-29 | Bracebridge Capital, LLC | 428.57K | 707.14K | 0.64% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 932.70K | 1.54M | 1.40% |
2023-06-29 | Vanguard Extended Market Index Fund | 493.68K | 814.56K | 0.74% |
2023-05-30 | Fidelity Extended Market Index Fund | 197.28K | 455.72K | 0.30% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 142.36K | 234.89K | 0.21% |
2023-08-30 | iShares Micro Cap ETF | 92.79K | 152.17K | 0.14% |
2023-05-30 | Fidelity Total Market Index Fund | 78.34K | 180.97K | 0.12% |
AQST 6-23-22
$AQST On 3-18-21 I bought 2500 shares @5.12 and I’ve still got it OUCH! Time will tell.
$AQST I can’t blame people for selling but why aren’t people buying this is so undervalued
$AQST I know that hurt I’m contemplating the same
$AQST Absolutely brutal
$AQST God save the Queen!
$AQST @GME My exact same words when I did the bulk of my buying at the 5.00 to 4.50 range holding a 4.20 avg. on a big bundle , alright BAG!
$AQST I’m holding a -38% sizable bag but I’ve got the faith we’re gonna make some MONEY!
$AQST Keep the faith
$AQST KEEP THA FAITH
$AQST CEO stated 10/06/21
This amendment of our Credit Facility, our access to the additional $30 million of debt under the Credit Facility, strong operating results and appropriate ATM access will continue to provide the capital to meet our immediate needs including the potential launch of Libervant, if approved by the FDA for U.S. market access. We continue to believe that Libervant, our non-invasive and innovative PharmFilm product candidate for refractory epilepsy, is well positioned to improve the quality of life for patients suffering from this disease with this first of its kind treatment option.”
$AQST Get that man a shrimp cocktail
$AQST We need to find a better location with more street traffic and advertise free shrimp cocktails with purchase of 100 shares
$AQST CEO stated 10/06/21
This amendment of our Credit Facility, our access to the additional $30 million of debt under the Credit Facility, strong operating results and appropriate ATM access will continue to provide the capital to meet our immediate needs including the potential launch of Libervant, if approved by the FDA for U.S. market access. We continue to believe that Libervant, our non-invasive and innovative PharmFilm product candidate for refractory epilepsy, is well positioned to improve the quality of life for patients suffering from this disease with this first of its kind treatment option.
$AQST Man those 10000 + shares felt so good going up but they hurt like hell going down
$AQST REPEAT “When your going through HELL, keep on going”. Winston Churchill